SEEKYO is a biotech company that provides chemotherapies without adverse effects. It develops a drug candidate that can specifically target solid tumors, such as pancreas, lung, triple-negative breast, colon, head and neck, while sparing healthy tissues. In addition, the company offers a molecular platform that can design targeting assembly in order to treat a given malignancy, based on its unique tumor-associated specificities.